On 4 May 2015, the National Development and Reform Commission, the National Health and Family Planning Commission, and four other ministerial departments of the Chinese central government jointly published the Notice of Promoting the Reform of Drug Pricing. As of 1 June 2015, the price ceiling for most drugs has been eliminated, with the intention of reducing government intervention in drug pricing and adopting a market-driven pricing system.
China Removes Price Ceilings from Most Drugs
By David J.D. Dai and John Z.L. Huang on June 16, 2015
Posted In Health and Welfare Plans
David J.D. DaiJunda (David) Dai represents a variety of European and US clients in their direct investments in China, including green-field investments, cross-border mergers and acquisitions (M&A), venture capital and private equity investments, and strategic alliances. Leveraging more than 15 years of post-qualification experience, he advises clients, including many Fortune 500 companies, in a wide range of industries and areas, from manufacturing, infrastructure, telecommunications, media and technology (TMT), chemicals and energy, to health care, life science and agriculture. David is co-head of the Corporate Advisory Group. Read Junda (David) Dai's full bio.
John Z.L. HuangRelated Posts
- Wild Ride Awaits Health, Life Sciences Policy in 2022
- Drug Prices Are Prime Target in Biden’s Competition Order
- How the Overturning of Roe v. Wade May Affect US Employer Benefits Plans
- HR Might Be on the Front Line in the Battle Against Monkeypox Misinformation
- HIPAA Faces Test in New Abortion Reality
BLOG EDITORS
STAY CONNECTED
TOPICS
ARCHIVES
RECENT POSTS
- Colorado Continues to Whittle Away at Non-Compete Agreements
- How the Overturning of Roe v. Wade May Affect US Employer Benefits Plans
- Save It for a Rainy Day: Recent Amendment Extensions for Qualified Retirement Plans, 403(b) Plans and Individual Retirement Accounts
- HR Might Be on the Front Line in the Battle Against Monkeypox Misinformation
- HIPAA Faces Test in New Abortion Reality
